Memantine in Patients With Chronic Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00168350
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : November 4, 2010
Information provided by:

Brief Summary:
Randomized double-masked clinical trial of memantine in patients with glaucoma

Condition or disease Intervention/treatment Phase
Open-Angle Glaucoma Drug: memantine Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1179 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : March 2000
Primary Completion Date : September 2006
Study Completion Date : September 2006

Primary Outcome Measures :
  1. Progression of glaucoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 82 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • glaucoma damage on examination of visual field and optic disc
  • good visual acuity (with glasses if needed) Identifier: NCT00168350     History of Changes
Other Study ID Numbers: 192944-005
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: November 4, 2010
Last Verified: November 2010

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents